Inhalte im Video:
Interview mit:
Interview von:
Produziert von:
ASH 2018: „Bei älteren Myelom-Patienten mehr Wert auf das geriatrische Assessment legen.”
OÄ Dr. Sonja Heibl, Abteilung für Innere Medizin IV, Klinikum Wels-Grieskirchen, über die Behandlung von älteren Myelom-Patienten und ihre Take-home-Messages vom ASH 2018 zu MDS und CLL
In diesem Video spricht Frau OÄ Dr. Heibl über folgende, am ASH präsentierte Vorträge:
- Approach to the Treatment of the Older, Unfit Patient With Myeloma: From Diagnosis to Relapse. Educational Program
https://ash.confex.com/ash/2018/webprogram/Session13558.html - Fenaux P et al.: The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions, #1
- Woyach JA et al.: Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. ASH 2018, #6
- Shanafelt TD et al.: A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912), #LBA-4
Weiterlesen